title: Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer.
abstract: OBJECTIVE
  Cytotoxic treatment may cause weight gain and important alterations in the metabolic status of breast cancer (BC) patients. The aim of this study was to investigate the changes in metabolic and anthropometric parameters of patients with BC who received adjuvant chemotherapy.
  
  
  METHODS
  All consecutive women treated with adjuvant TAC (docetaxel 75 mg/m(2), doxorubicine 50 mg/m(2), cyclophosphamide 500 mg/m(2)) chemotherapy for node-positive breast carcinoma at our Institution between 2008 and 2010 were included.
  
  
  RESULTS
  Among 104 patients, 84 of them were stage II and 20 of them were stage III. When we compared the measurements between 1(st) and 6(th) adjuvant chemotherapy, we observed statistically significant increases in weight and serum triglyceride levels, and decreases in high density lipoprotein, apolipoprotein A-1, transferrin, albumin and prealbumin levels. An elevation of follicle stimulating hormone, luteinizing hormone together with the decrease of estradiol was detected. Waist-to-hip ratio has also increased significantly. In subgroup analyses, we observed dramatic changes in body mass index in pre-menopausal women whereas no significant change was seen in the post-menopausal group.
  
  
  CONCLUSIONS
  Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with BC and these changes are more profound in pre-menopausal patients.
authors.affiliation: Division of Medical Oncology, Tulay Aktas Oncology Hospital, School of Medicine, Ege University, Izmir, Turkey.
authors.forename: Derya Hopanci
authors.initials: DH
authors.lastname: Bicakli
authors.affiliation: Division of Medical Oncology, Tulay Aktas Oncology Hospital, School of Medicine, Ege University, Izmir, Turkey varolumut@yahoo.com.
authors.forename: Umut
authors.initials: U
authors.lastname: Varol
authors.affiliation: Division of Medical Oncology, Tulay Aktas Oncology Hospital, School of Medicine, Ege University, Izmir, Turkey.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Degirmenci
authors.affiliation: Division of Medical Oncology, Tulay Aktas Oncology Hospital, School of Medicine, Ege University, Izmir, Turkey.
authors.forename: Didem
authors.initials: D
authors.lastname: Tunali
authors.affiliation: Division of Medical Oncology, Tulay Aktas Oncology Hospital, School of Medicine, Ege University, Izmir, Turkey.
authors.forename: Burcu
authors.initials: B
authors.lastname: Cakar
authors.affiliation: Department of Public Health, School of Medicine, Ege University, Bornova, Izmir, Turkey.
authors.forename: Raika
authors.initials: R
authors.lastname: Durusoy
authors.affiliation: Division of Medical Oncology, Tulay Aktas Oncology Hospital, School of Medicine, Ege University, Izmir, Turkey.
authors.forename: Burcak
authors.initials: B
authors.lastname: Karaca
authors.affiliation: Division of Medical Oncology, Tulay Aktas Oncology Hospital, School of Medicine, Ege University, Izmir, Turkey.
authors.forename: Ulus
authors.initials: U
authors.lastname: Ali Sanli
authors.affiliation: Division of Medical Oncology, Tulay Aktas Oncology Hospital, School of Medicine, Ege University, Izmir, Turkey.
authors.forename: Ruchan
authors.initials: R
authors.lastname: Uslu
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000209:etiology*; D008875:Middle Aged; D012306:Risk; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D003520:Cyclophosphamide
keywords: Breast cancer; adjuvant chemotherapy; metabolic syndrome